| Drug Name: | Calan |
| Manufacturer: | G.D. Searle LLC |
| Other Info: | Rx onlyLAB-0269-3.0 |
| Clinical Trials: | |
Verapamil HCl tablets are contraindicated in:Severe left ventricular dysfunction (see Warnings)Hypotension (systolic pressure less than 90 mm Hg) or cardiogenic shockSick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker)Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (eg, Wolff-Parkinson-White, Lown-Ganong-Levine syndromes).
(See Warnings.)Patients with known hypersensitivity to verapamil hydrochloride.Verapamil has a negative inotropic effect, which in most patients is compensated by its afterload reduction (decreased systemic vascular resistance) properties without a net impairment of ventricular performance.
In clinical experience with 4,954 patients, 87 (1.8%) developed congestive heart failure or pulmonary edema.
Verapamil should be avoided in patients with severe left ventricular dysfunction (eg, ejection fraction less than 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (see Drug interactions).
Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment.
(Note interactions with digoxin under Precautions.)